Yoshiya Toyoda

Prof. Dr. Yoshiya Toyoda

Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
Yoshiya ToyodaYoshiya Toyoda
Yoshiya Toyoda
JBJay K. Bhama
Jay K. Bhama
NSNorihisa Shigemura
Norihisa Shigemura
DZDiana Zaldonis
Diana Zaldonis
JPJoseph Pilewski
Joseph Pilewski
CBChristian Bermudez
Christian Bermudez

1 January 2016 in Transplantation
Verified
Journal Article
Closed access
EREmily M. Rosenberger
Emily M. Rosenberger
ADAndrea F. DiMartini
Andrea F. DiMartini
ADAnnette J. DeVito Dabbs
Annette J. DeVito Dabbs
CBChristian A. Bermudez
Christian A. Bermudez
JPJoseph M. Pilewski
Joseph M. Pilewski
MDMary Amanda Dew
Mary Amanda Dew
Background Long-term survival after lung transplantation remains poor, yet modifiable risk factors for late-term morbidity and mortality have yet to be identified. Because psychiatric disorders increase risk for poor health outcomes in many nontransplant chronic disease populations, lung recipients with depression or anxiety before or early after transplantation may be at heightened risk for late-term transplant-related morbidity and mortality. Methods Among 178 patients from a prospective study of mental health after lung transplantation, we identified 1-year survivors and examined whether they experienced major depression or anxiety disorders during that year as well as before transplantation. We used multivariable Cox regression to examine the relationship between these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and graft loss for up to 15 years posttransplant, controlling for other known risk factors for the outcomes. Results One hundred fifty-five recipients were studied. Recipients with posttransplant depression had an elevated risk of BOS (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 1.10-3.31), patient death (HR, 1.65; 95% CI, 1.01-2.71) and graft loss (HR, 1.75; 95% CI, 1.06-2.88). A trend toward reduced risk of BOS was observed in recipients with posttransplant anxiety (HR, 0.61; 95%CI, 0.37-1.00). Neither pretransplant disorder was related to risk for any outcome. Conclusions Early posttransplant depression increases risk for long-term transplant-related morbidity and mortality. Screening to identify depression should therefore be routine in posttransplant care. Although anxiety was not significantly associated with poor outcomes, screening for posttransplant anxiety should also be routine, to reduce patient distress. Research is needed to better understand mechanisms underlying depression-outcome associations.

1 January 2013 in Circulation Journal
Verified
Journal Article
Open access
PDF file
Yoshiya ToyodaYoshiya Toyoda
Yoshiya Toyoda
TGT. Sloane Guy
T. Sloane Guy
AKAbul Kashem
Abul Kashem
Heart transplantation has evolved as the “gold standard” therapy, with median survival exceeding 10 years, for patients with endstage heart failure (HF). Advancements in the fields of immunosuppression, infection prophylaxis, and surgical techniques have transformed heart transplantation from what was once considered an experimental intervention into a routine treatment. The number of heart transplants reported to the International Society of Heart and Lung Transplantation registry worldwide has been 3,500–4,000 annually, but has not been increased over the past 2 decades because of donor shortage despite the growing number of patients with HF. This imbalance between the supply of donor hearts and the demand of patients with endstage HF has led to increased use of mechanical circulatory support as destination therapy, because the supply of mechanical devices is virtually unlimited. Although mechanical circulatory support technology is improving, heart transplantation remains the preferred treatment for many patients because of major complications, such as stroke, bleeding and infection, and because of limited quality of life related to the driveline and the need for battery change. Therefore, significant efforts have been made to maximize the number of heart transplants and to ensure good outcomes. (Circ J 2013; 77: 1097–1110)

2 February 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YFY. Furuya
Y. Furuya
SJS. N. Jayarajan
S. N. Jayarajan
STS. Taghavi
S. Taghavi
FCF. C. Cordova
F. C. Cordova
NPN. Patel
N. Patel
Yoshiya ToyodaYoshiya Toyoda
Yoshiya Toyoda
We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk‐adjusted all‐cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no‐induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.

9 January 2015 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
SJSenthil Jayarajan
Senthil Jayarajan
STSharven Taghavi
Sharven Taghavi
EKEugene Komaroff
Eugene Komaroff
ASAkira Shiose
Akira Shiose
DSDaniel Schwartz
Daniel Schwartz
Yoshiya ToyodaYoshiya Toyoda
Yoshiya Toyoda
Organ donors with a history of cocaine use are thought to be less favourable for orthotopic heart transplantation (OHT). This study examined long-term survival in OHT using donors with a history of cocaine use. The United Network for Organ Sharing (UNOS) database was examined for primary, adult heart transplants from 2000 to 2010. Cox proportional hazards analysis using covariates associated with mortality was used to examine survival. There were 19 636 total OHTs with 2274 (11.6%) using donors with a history of dependent cocaine use (DCU). Of these, 1008 (44.3%) donors were current cocaine users. Recipients of DCU were more likely to be male (79.0 vs 75.7%, P < 0.001), more likely diabetic (16.5 vs 14.8%, P = 0.003) and were less likely to be sex mismatched (23.0 vs 28.6%, P < 0.001). DCU donors were older (32.5 vs 31.4 years, P < 0.001), more likely male (79.7 vs 69.8%, P < 0.001) and had higher ischaemic times (3.27 vs 3.20 h, P = 0.001). On multivariate analysis, DCU was not associated with mortality [hazard ratio (HR): 0.95, 95% CI: 0.87–1.03, P = 0.22]. Variables associated with mortality included recipient body mass index, sex mismatch, race mismatch, black race, ischaemic time, recipient creatinine, donor age, donor smoking history and mechanical ventilation or extracorporeal membrane oxygen as a bridge to transplantation. On subset analysis, CCU was not associated with mortality (HR: 0.97, 95% CI: 0.89–1.05, P = 0.42). On Kaplan–Meier analysis, median survival was not different when comparing current (3890.0 days), past (3,889.0 days) and non-cocaine using donors (4165.0 days); P = 0.54. Use of carefully selected donors with a history of past and current cocaine use does not result in worse outcomes.

15 January 2014 in Transplantation
Verified
Journal Article
Closed access
SJSenthil N. Jayarajan
Senthil N. Jayarajan
STSharven Taghavi
Sharven Taghavi
EKEugene Komaroff
Eugene Komaroff
SBStacey Brann
Stacey Brann
THTetsuya Horai
Tetsuya Horai
Yoshiya ToyodaYoshiya Toyoda
Yoshiya Toyoda
Background Extracorporeal membrane oxygenation (ECMO) and mechanical ventilation (MV) can be used as a bridge to heart-lung transplantation (HLT). The goal of this study was to determine if pretransplantation ECMO or MV affects survival in HLT. Methods The United Network for Organ Sharing database was reviewed for all adult patients receiving HLT from 1995 to 2011. The primary outcome measured was risk-adjusted all cause mortality. Results There were 542 adult patients received HLT during the study period. Of these, 15 (2.8%) required ECMO and 22 (4.1%) required MV as a bridge to transplantation. The groups were evenly matched with regards to recipient age, recipient gender, ischemic time, donor age, and donor gender. The ECMO cohort had worse survival than the control group at 30 days (20.0% vs. 83.5%) and 5 years (20.0% vs. 47.4%; P<0.001). When compared with control, patients requiring MV had worse survival at 1 month (77.3% vs. 83.5%) and 5 years (26.5% vs. 47.4%; P<0.001). The use of ECMO (hazard ratio [HR]=3.820, 95% confidence interval [CI]=1.600–9.116; P=0.003) or MV (HR=2.011, 95% CI=1.069–3.784; P=0.030) as a bridge to transplantation was independently associated with mortality on multivariate analysis. Recipient female gender was associated with survival (HR=0.754, 95% CI=0.570–0.998; P=0.048). Conclusions HLT recipients bridged by MV or ECMO have increased short-term and long-term mortality. Further studies are needed to optimize survival in these high-risk patients.